• Profile

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer

The Breast Jan 06, 2022

Nakajima H, Harano K, Nakai T, et al. - In tumors with heterogeneous, reduced, or loss of HER2 expression, the previous second-line treatment for HER2-positive metastatic breast cancer, ado-trastuzumab emtansine (T-DM1), shows reduced activity. Researchers herein investigated the ability of trastuzumab deruxtecan (T-DXd), a recently developed novel antibody-drug conjugate, to overcome resistance to T-DM1.

  • Researchers enrolled 22 patients with HER2-positive metastatic breast cancer who received T-DXd.

  • Favorable clinical activity was demonstrated by T-DXd against HER2-positive metastatic breast cancer.

  • Patients with heterogeneity, reduction, or loss of HER2 expression benefited in correlation with receiving T-DXd.

  • Tendency to experience worse outcomes was recorded for patients with liver metastasis.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen